Fierce Biotech
Kailera, Hengrui tout up to 12% weight loss in midstage study for obesity pill
In October of last year, Kailera Therapeutics unveiled a whopping $600 mill | Kailera Therapeutics and its China partner Hengrui have released top-line results from a phase 2 trial of their oral version of ribupatide that indicate it has a “potentially game-changing clinical profile,” according to …
